For patients with recurrent ovarian cancer, trebananib did not improve overall survival
the ONA take:
Amgen has announced secondary endpoint results from its TRINOVA-1 study that investigated trebananib plus paclitaxel for the treatment of patients with recurrent ovarian cancer.
The combination therapy did not show a statistically significant improvement in overall survival compared with placebo plus paclitaxel. The TRIANOVA-1 study is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial that evaluated trebananib in combination with weekly paclitaxel in women with epithelial ovarian, primary peritoneal, or fallopian tube cancer.
Researchers randomly assigned patients to receiver either trebananib 15mg/kg intravenously weekly plus paclitaxel 80mg/m2 intravenously weekly for 3 weeks for 4-week cycles or placebo plus paclitaxel 80mg/m2 intravenously weekly for 3 weeks for 4-week cycles.
Amgen previously announced positive primary endpoint results that showed a statistically significant improvement in progression-free survival in the trebananib group, but secondary endpoint results showed a median overall survival of 19.3 months among those who received trebananib and 18.3 months among those who received placebo.
Despite the disappointing results, trebananib is also being studied in other combinations for the same three cancers. Trebananib is an investigational peptibody that ultimately inhibits angiogenesis, thereby causing cancer cell death.
Results from TRINOVA-1 study that investigated trebananib plus paclitaxel for ovarian cancer.
Amgen today announced the top-line secondary endpoint results of overall survival from the Phase 3 TRINOVA-1 trial in women with recurrent platinum-resistant ovarian cancer.
The study, which evaluated trebananib plus paclitaxel versus placebo plus paclitaxel, did not demonstrate a statistically significant improvement in overall survival. Median overall survival was 19.3 months in the trebananib arm versus 18.3 months in the control arm. The data will be submitted to a future medical conference and for publication.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|